Aoyi Technology Raises Nearly ¥100M in B++ Round to Lead Next-Gen Dexterous Robotics and Brain-Computer Interface Innovation

Aoyi Technology Secures Nearly ¥100M in B++ Round to Accelerate Breakthroughs in Dexterous Robotics and Neurotechnology

Shanghai Aoyi Information Technology Co., Ltd. (“Aoyi Technology”) has announced the successful completion of its B++ financing round, raising nearly ¥100 million. The round was jointly led by Infiniti Capital, Zhejiang State-Owned Capital Operation Co., Ltd., and Womed Capital, with Shengkeji Capital serving as long-term financial advisor.

This funding comes just three months after the company closed its B+ round at the end of 2024, highlighting Aoyi’s rapid growth momentum and strong market validation.

 Fueling Breakthrough Innovation in Dexterous Hands and Neuro-Robotics

The newly raised capital will be directed toward several key initiatives, including:

• Accelerating R&D in dexterous hand technology

• Commercial launch of the next-generation dexterous hand

• Fast-tracking the market entry of finger joint exoskeleton robots

• Establishing a world-class standardized production system to double annual production capacity

• Expanding global market presence to deliver smarter, faster, and more efficient solutions to international clients

Founded in 2015 in Shanghai’s Zhangjiang Hi-Tech Park, Aoyi is one of the few Chinese tech firms to master both brain-computer interface (BCI) and robotic core technologies. The company has built a unique three-pillar R&D platform combining neural interface, robotics, and AI algorithms, enabling the development of cutting-edge products recognized globally for both performance and commercial viability.

From Neuroscience to Dexterous Robotics: The Future is Embodied

Aoyi’s first dexterous hand product has already been deployed by multiple humanoid robot manufacturers and received high acclaim. As a mission-critical upstream solution for general-purpose robots, dexterous hands are known for their technological complexity and demanding precision—a field long plagued by the “impossible triangle” of cost, system parameters, and stability.

Since 2017, Aoyi’s expert team has iterated dozens of product versions and achieved wide application across diverse use cases:

• EMG-powered bionic prosthetic hands for amputees

• Multi-model dexterous hands tailored for embodied AI clients

• Finger joint exoskeletons to assist users with motor impairments

The flagship product, ROH-A001, is among the few on the market with scalable production and mass delivery capabilities. Through extensive SKU development for different scenarios, Aoyi has balanced the “impossible triangle” and emerged as a tier-one player in the dexterous hand industry.

Coming soon, Aoyi will launch ROH-AP001, a new generation dexterous hand featuring advanced sensory capabilities such as tactile and pressure feedback, further strengthening its product lineup.

Leading Globalization of Chinese Brain-Robot Innovations

In the neuroscience field, Aoyi has created a medical-grade neural interface platform, integrating both hardware and software. With over 80 patents to date, its product ecosystem includes:

• OB Series Brain-Computer Interfaces

• OHand™ Smart Bionic Hands

• ORF Series Neurorehabilitation Exoskeletons

The OHand™, launched in 2020, quickly gained traction by offering top-tier technology at a competitive price, seizing market share from foreign competitors. In 2023, the product achieved FDA and CE certifications, along with the PDAC reimbursement code in the U.S., paving the way for commercialization in the U.S., Middle East, Russia, Ukraine, India, and beyond. Today, OHand™ is a shining example of China’s intelligent manufacturing on the global stage.

A Milestone for China’s Brain-Robot Industry

Completing two funding rounds in such a short span marks a milestone in Aoyi Technology’s journey. Moving forward, the company will continue to uphold its mission—innovation-driven, market-oriented, and collaboration-focused.

Founder and CEO Hualiang Ni stated:

“We sincerely thank our investors for their ongoing trust and support. Completing two successful rounds in just months is a strong endorsement of our company’s vision and momentum. With this new capital, Aoyi will deepen cooperation across the ecosystem and advance the commercialization of brain-science and robotics, aiming to become a globally leading technology enterprise.”